Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

by Thomas Prébet, Sylvain Thepot, Steven D. Gore, François Dreyfus, Pierre Fenaux, Norbert Vey
Published 2013-02-01

Epigenetics in Cancer: A Hematological Perspective.

by Maximilian Stahl, Nathan Kohrman, Steven D Gore, Tae Kon Kim, Amer M Zeidan, Thomas Prebet
Published 2016-10-01

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

by Sheila Weiss Smith, Masayo Sato, Steven D. Gore, Maria R. Baer, Xuehua Ke, Diane McNally, Amy Davidoff
Published 2012-01-01

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

by Dan P. Zandberg, Ting-Ying Huang, Xuehua Ke, Maria R. Baer, Steven D. Gore, Sheila Weiss Smith, Amy J. Davidoff
Published 2013-04-01

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

by Amy J. Davidoff, Sheila Weiss Smith, Maria R. Baer, Xuehua Ke, Jason M. Bierenbaum, Franklin Hendrick, Diane L. McNally, Steven D. Gore
Published 2012-01-01

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

by Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J MacBeth
Published 2015-01-01

A phase 2 study of vorinostat in acute myeloid leukemia

by Eric W. Schaefer, Arturo Loaiza-Bonilla, Mark Juckett, John F. DiPersio, Vivek Roy, James Slack, Wenting Wu, Kristina Laumann, Igor Espinoza-Delgado, Steven D. Gore
Published 2009-10-01

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care...

by Steven D. Gore, Pierre Fenaux, Valeria Santini, John M. Bennett, Lewis R. Silverman, John F. Seymour, Eva Hellström-Lindberg, Arlene S. Swern, Charles. L. Beach, Alan. F. List
Published 2013-07-01

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

by Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, Renier J Brentjens, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, John M Pagel, Martin S Tallman
Published 2020-07-01

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia

by Nikolai A. Podoltsev, Rong Wang, Rory M. Shallis, Jessica M. Stempel, Mengyang Di, Natalia Neparidze, Amer M. Zeidan, Scott F. Huntington, Smith Giri, Sarah C. Hull, Steven D. Gore, Xiaomei Ma
Published 2023-09-01

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

by Amer M Zeidan, Jessica B Long, Rong Wang, Xin Hu, James B Yu, Scott F Huntington, Gregory A Abel, Sarah S Mougalian, Nikolai A Podoltsev, Steven D Gore, Cary P Gross, Xiaomei Ma, Amy J Davidoff
Published 2017-01-01

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

by Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt
Published 2014-04-01

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk a...

by Judith E. Karp, Elizabeth Garrett-Mayer, Elihu H. Estey, Michelle A. Rudek, B. Douglas Smith, Jacqueline M. Greer, D. Michelle Drye, Karen Mackey, Kathleen Shannon Dorcy, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle, John J. Wright, John M. Pagel
Published 2012-11-01